NASDAQ:GLUE Monte Rosa Therapeutics (GLUE) Stock Price, News & Analysis $4.97 +0.10 (+2.05%) Closing price 04:00 PM EasternExtended Trading$5.01 +0.04 (+0.87%) As of 07:04 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Monte Rosa Therapeutics Stock (NASDAQ:GLUE) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get GLUE alerts:Sign Up Key Stats Today's Range$4.73▼$5.1350-Day Range$3.70▼$5.0852-Week Range$3.50▼$12.40Volume465,652 shsAverage Volume1.08 million shsMarket Capitalization$305.70 millionP/E Ratio62.13Dividend YieldN/APrice Target$15.33Consensus RatingModerate Buy Company Overview Monte Rosa Therapeutics (NASDAQ:GLUE) is a biotechnology company focused on the discovery and development of small-molecule therapies that harness targeted protein degradation to treat a broad range of diseases. The company’s approach centers on molecular glues and bifunctional degraders, which recruit the cell’s natural protein disposal machinery to selectively eliminate disease-causing proteins. Monte Rosa’s lead research areas include oncology and immunology, with a pipeline of discovery-stage programs designed to address both solid tumors and hematologic malignancies. At the core of Monte Rosa’s efforts is a proprietary platform that integrates computational biology, chemoproteomics and medicinal chemistry. This platform allows rapid identification of novel degrader candidates and optimization of their pharmacologic properties. By combining high-throughput screening with machine learning algorithms, the company accelerates the translation of early-stage hits into development candidates, enabling a more efficient path to the clinic. Since its founding in 2019, Monte Rosa has established collaborations and research partnerships with leading pharmaceutical and academic institutions to expand its target space and validate degrader modalities. The company’s research facilities are headquartered in Cambridge, Massachusetts, and it maintains a strategic research presence in the United Kingdom to leverage regional expertise and foster transatlantic scientific exchange. Monte Rosa is led by a seasoned team of executives and scientific leaders with decades of experience in drug discovery, translational research and clinical development. The senior leadership includes professionals who have held key roles in both emerging biotech firms and established pharmaceutical companies, guiding the organization’s strategic vision and advancing its mission to develop transformative therapies for patients with unmet medical needs.AI Generated. May Contain Errors. Read More Monte Rosa Therapeutics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks27th Percentile Overall ScoreGLUE MarketRank™: Monte Rosa Therapeutics scored higher than 27% of companies evaluated by MarketBeat, and ranked 791st out of 913 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.3 / 5Analyst RatingModerate Buy Consensus RatingMonte Rosa Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.67, and is based on 2 buy ratings, 1 hold rating, and no sell ratings.Amount of Analyst CoverageMonte Rosa Therapeutics has received no research coverage in the past 90 days.Read more about Monte Rosa Therapeutics' stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Monte Rosa Therapeutics are expected to grow in the coming year, from ($1.49) to ($1.41) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Monte Rosa Therapeutics is 62.26, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 25.73.Price to Earnings Ratio vs. SectorThe P/E ratio of Monte Rosa Therapeutics is 62.26, which means that it is trading at a more expensive P/E ratio than the Medical sector average P/E ratio of about 27.27.Price to Book Value per Share RatioMonte Rosa Therapeutics has a P/B Ratio of 1.37. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about Monte Rosa Therapeutics' valuation and earnings. Short Interest0.0 / 5Short Interest LevelBearish Percentage of Shares Shorted19.29% of the float of Monte Rosa Therapeutics has been sold short.Short Interest Ratio / Days to CoverMonte Rosa Therapeutics has a short interest ratio ("days to cover") of 15, which indicates bearish sentiment.Change versus previous monthShort interest in Monte Rosa Therapeutics has recently increased by 9.78%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldMonte Rosa Therapeutics does not currently pay a dividend.Dividend GrowthMonte Rosa Therapeutics does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted19.29% of the float of Monte Rosa Therapeutics has been sold short.Short Interest Ratio / Days to CoverMonte Rosa Therapeutics has a short interest ratio ("days to cover") of 15, which indicates bearish sentiment.Change versus previous monthShort interest in Monte Rosa Therapeutics has recently increased by 9.78%, indicating that investor sentiment is decreasing significantly. News and Social Media0.9 / 5News SentimentN/A News SentimentMonte Rosa Therapeutics has a news sentiment score of -0.46. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.58 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 1 news article for Monte Rosa Therapeutics this week, compared to 2 articles on an average week. Company Ownership1.7 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Monte Rosa Therapeutics insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 6.50% of the stock of Monte Rosa Therapeutics is held by insiders.Percentage Held by Institutions79.96% of the stock of Monte Rosa Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Monte Rosa Therapeutics' insider trading history. Receive GLUE Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Monte Rosa Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address GLUE Stock News HeadlinesMonte Rosa Announces Publication in Science of Key Insights that Enable Next Generation Molecular Glue Degrader MedicinesJuly 3, 2025 | globenewswire.comMonte Rosa Therapeutics Announces FDA Clearance of IND Application for MRT-8102, a NEK7-Directed Molecular Glue Degrader for the Treatment of Multiple Inflammatory DiseasesJune 10, 2025 | globenewswire.comTrump Makes Major Crypto AnnouncementPay close attention to what I'm about to share… Most investors think Trump's pro-crypto policies will lift all boats equally. They're wrong. One project stands to benefit more than any other – not by accident, but seemingly by design. July 7 at 2:00 AM | Crypto 101 Media (Ad)Monte Rosa Therapeutics to Participate in the Jefferies Global Healthcare ConferenceMay 28, 2025 | globenewswire.comMonte Rosa Therapeutics Announces First Quarter 2025 Financial Results and Business UpdatesMay 8, 2025 | globenewswire.comMonte Rosa Therapeutics Presents Preclinical Data at American Association for Cancer Research (AACR) Annual Meeting 2025 on the Potential of its CDK2-directed Molecular Glue Degrader to Treat HR-positive/HER2-negative Breast CancerApril 28, 2025 | globenewswire.comMonte Rosa Therapeutics Insider Ups Holding During YearApril 22, 2025 | finance.yahoo.comMonte Rosa Therapeutics: Exercise Extreme CautionMarch 25, 2025 | seekingalpha.comSee More Headlines GLUE Stock Analysis - Frequently Asked Questions How have GLUE shares performed this year? Monte Rosa Therapeutics' stock was trading at $6.94 at the start of the year. Since then, GLUE stock has decreased by 28.2% and is now trading at $4.98. How were Monte Rosa Therapeutics' earnings last quarter? Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE) released its quarterly earnings data on Thursday, May, 8th. The company reported $0.57 EPS for the quarter, beating analysts' consensus estimates of ($0.24) by $0.81. The business earned $84.93 million during the quarter, compared to analyst estimates of $13.57 million. Monte Rosa Therapeutics had a net margin of 3.86% and a trailing twelve-month return on equity of 2.65%. When did Monte Rosa Therapeutics IPO? Monte Rosa Therapeutics (GLUE) raised $211 million in an IPO on Thursday, June 24th 2021. The company issued 11,700,000 shares at a price of $17.00-$19.00 per share. How do I buy shares of Monte Rosa Therapeutics? Shares of GLUE stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Monte Rosa Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Monte Rosa Therapeutics investors own include AU Optronics (AUOTY), Waste Connections (WCN), American Water Works (AWK), The RMR Group (RMR), DiamondRock Hospitality (DRH), iShares Micro-Cap ETF (IWC) and Triple Flag Precious Metals (TFPM). Company Calendar Last Earnings5/08/2025Today7/07/2025Next Earnings (Estimated)8/14/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - BIOMED/GENE Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:GLUE CIK1826457 Webwww.monterosatx.com Phone617-949-2643FaxN/AEmployees90Year FoundedN/APrice Target and Rating Average Stock Price Target$15.33 High Stock Price Target$19.00 Low Stock Price Target$10.00 Potential Upside/Downside+207.9%Consensus RatingModerate Buy Rating Score (0-4)2.67 Research Coverage3 Analysts Profitability EPS (Trailing Twelve Months)$0.08 Trailing P/E Ratio62.26 Forward P/E RatioN/A P/E GrowthN/ANet Income-$72.70 million Net Margins3.86% Pretax Margin5.93% Return on Equity2.65% Return on Assets1.65% Debt Debt-to-Equity RatioN/A Current Ratio5.61 Quick Ratio5.61 Sales & Book Value Annual Sales$75.62 million Price / Sales4.05 Cash FlowN/A Price / Cash FlowN/A Book Value$3.63 per share Price / Book1.37Miscellaneous Outstanding Shares61,510,000Free Float57,512,000Market Cap$306.32 million OptionableOptionable Beta1.41 10 "Recession Proof" Stocks That Will Thrive in Any MarketWhich stocks are likely to thrive in today's challenging market? Enter your email address and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.Get This Free Report This page (NASDAQ:GLUE) was last updated on 7/7/2025 by MarketBeat.com Staff From Our PartnersA grave, grave error.I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | SponsoredThis Signal Only Flashes Once Every 4 Years – And It Just TriggeredThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredPresidential Bombshell: $150T Resource to Be Released as soon as this Summer?Something extraordinary is happening in Washington. For the first time in over a century, a sitting Preside...Paradigm Press | SponsoredBanks aren’t ready for this altcoin—are you?Our expert analysts have identified a $100 billion gap in the crypto market. Only one project is perfectly ...Crypto 101 Media | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredIs Elon's empire crumbling?The Tesla Shock Nobody Sees Coming While headlines scream "Tesla is doomed"... Jeff Brown has uncovered ...Brownstone Research | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Monte Rosa Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Monte Rosa Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.